多形性膠質母細胞瘤治療藥(GBM)市場:現狀分析與預測(2022-2030年)

Glioblastoma Multiforme Treatment (GBM) Market: Current Analysis and Forecast (2022-2030)

出版日期: 2023年05月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

多形性膠質母細胞瘤 (GBM) 是一種侵襲性腦腫瘤，由神經膠質細胞產生，神經膠質細胞是支持和保護大腦神經細胞的細胞。它是最常見的惡性原發性腦腫瘤，約佔所有腦腫瘤的15%。多形性膠質母細胞瘤患病率的增加是推動多形性膠質母細胞瘤治療市場增長的關鍵因素。例如，根據國家腦腫瘤協會的數據，GBM 佔所有原發性惡性腦腫瘤的 49.1%。據估計，美國每年有超過 10,000 人死於膠質母細胞瘤。

為了更好地了解行業市場採用情況，市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、意大利、西班牙、歐洲其他地區）、亞太地區（中國）、日本，根據印度、韓國、澳大利亞和亞太地區其他國家/地區的全球影響力進行分析）、世界其他地區。北美已成為治療多形性膠質母細胞瘤的重要市場。這主要是由於膠質母細胞瘤的高患病率以及該地區現有的基礎設施，從而促進了該地區多形性膠質母細胞瘤治療的顯著增長。該地區越來越多的人正在尋求替代和補充療法來補充其傳統醫療保健，並引入了醫療補貼來控制醫療費用。此外，該地區提供綜合療法的醫院數量不斷增加也是該地區市場增長的一個因素。例如，根據美國腦腫瘤協會的數據，到 2022 年，將有超過 13,000 名美國人被診斷出患有多形性膠質母細胞瘤。

北美的多形性膠質母細胞瘤治療(GBM)市場
- 美國
- 加拿大
- 其他北美地區
歐洲的多形性膠質母細胞瘤治療(GBM)市場
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲地區
亞太地區的多形性膠質母細胞瘤治療(GBM)市場
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- APAC的其他各國
其他地區的多形性膠質母細胞瘤治療(GBM)市場

第10章多形性膠質母細胞瘤治療(GBM)市場動態

推動市場要素
市場課題
影響分析

第11章多形性膠質母細胞瘤治療(GBM)市場機會

第12章多形性膠質母細胞瘤治療(GBM)市場趨勢

第13章需求面和供給面的分析

需求面分析
供給面分析

第14章價值鏈分析

第15章價格分析

第16章策略性洞察能力

第17章競爭模式

競爭情形
- 波特的五力分析

第18章企業簡介

Merck & Co., Inc.
Amgen Inc.
F. Hoffmann-La Roche Ltd
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals LLC
Karyopharm
Sumitomo Pharma Oncology, Inc
Bristol-Myers Squibb Company

第19章免責聲明

簡介目錄

Product Code: UMHE2118014

Glioblastoma multiforme (GBM) is a type of aggressive brain cancer that develops from glial cells, which are cells that support and protect nerve cells in the brain. It is the most common and malignant form of primary brain tumor, accounting for about 15% of all brain tumors. The increasing prevalence of the glioblastoma multiforme is the major factor responsible for the market growth of the glioblastoma multiforme treatment market. For instance, As per the National Brain Tumor Society, GBM accounts for 49.1% of all primary malignant brain tumors. It is estimated that more than 10,000 people die from glioblastoma each year in the United States.

Glioblastoma Multiforme Treatment (GBM) Market is expected to grow at a strong CAGR of 8% during the forecast period owing to favorable governmental policies on brain cancer treatment. For instance, in December 2022, The Australian Brain Tumor Mission invested USD 136.66 million to support brain tumor research. The goal is to double survival rates and improve the quality of life for brain tumor patients.

Based on treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating Field (TTF) therapy, and immunotherapy. The radiation therapy segment acquired a major share in 2021. Radiation therapy uses high-energy radiation to kill cancer cells and shrink tumors. It is often used in combination with other treatments, such as surgery and chemotherapy, to improve the chances of success. The increasing incidence of brain tumors, the growing demand for personalized cancer treatment options, and the rising adoption of advanced radiation therapy technologies are the major attributing factor to the considerable share of radiation therapy in the GBM treatment market.

Based on the end-use, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The clinics segment is expected to grow with the highest CAGR during the forecast period. The clinics in the GBM treatment market offer a variety of services, including imaging and diagnostic tests to confirm the presence of GBM, surgical procedures to remove tumors, radiation therapy to kill cancer cells, and chemotherapy to destroy cancer cells that have spread to other parts of the body are the main reason for the segmental growth.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America is a significant market for glioblastoma multiforme treatment. This is mainly due to the high prevalence of glioblastoma, along with the presence of the well-established infrastructure in the region attributes to the significant growth of the region in the glioblastoma multiforme treatment in the region. , with a growing number of people seeking out alternative and complementary therapies to supplement their conventional healthcare. Further, the region is also witnessing an increasing number of hospitals catering to integrative therapies also attributes to the growth of the market in the region. For instance, as per the National Brain Tumor Society, more than 13,000 Americans were diagnosed with glioblastoma multiforme in 2022.

Some of the major players operating in the market include: Merck & Co., Inc.; Amgen Inc.; F. Hoffmann-La Roche Ltd; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Amneal Pharmaceuticals LLC; Karyopharm; Sumitomo Pharma Oncology, Inc; and Bristol-Myers Squibb Company.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Glioblastoma Multiforme Treatment (GBM) Market
2.2. Research Methodology of the Glioblastoma Multiforme Treatment (GBM) Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT (GBM) MARKET COVID-19 IMPACT

6 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT (GBM) MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY TREATMENT

7.1. Surgery
7.2. Radiation therapy
7.3. Chemotherapy
7.4. Targeted Therapy
7.5. Tumor Treating Field (TTF) Therapy
7.6. Immunotherapy

8 MARKET INSIGHTS BY END-USE

8.1. Hospitals
8.2. Clinics
8.3. Ambulatory Surgical Centers
8.4. Others

9 MARKET INSIGHTS BY REGION

9.1. North America Glioblastoma Multiforme Treatment (GBM) Market
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe Glioblastoma Multiforme Treatment (GBM) Market
- 9.2.1. Germany
- 9.2.2. UK
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Market
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of APAC
9.4. Rest of the World Glioblastoma Multiforme Treatment (GBM) Market